By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences and the Buck Institute for Research on Aging announced today a collaboration to develop mass spectrometry-based tests aimed at improving response to breast cancer therapies.

Under the terms of the deal, Proteome Sciences will support the development of mass spec assays that measure changes in estrogen receptor alpha, a biomarker associated with response to anti-estrogen therapies for breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.